UnitedHealth Group (UNH, Financial) has reported a lackluster performance for the first quarter of 2025, expressing dissatisfaction with the outcomes. During the company's earnings conference call, executives noted that the pace of growth in care activities is currently doubling that of the previous year.
However, the company's Optum Rx division offers a silver lining, as it is experiencing a strong start to its selling season for 2025. This development offers some optimism for the healthcare giant as it seeks to improve its performance in the upcoming quarters.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 25 analysts, the average target price for UnitedHealth Group Inc (UNH, Financial) is $639.88 with a high estimate of $703.00 and a low estimate of $518.76. The average target implies an upside of 9.37% from the current price of $585.04. More detailed estimate data can be found on the UnitedHealth Group Inc (UNH) Forecast page.
Based on the consensus recommendation from 29 brokerage firms, UnitedHealth Group Inc's (UNH, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for UnitedHealth Group Inc (UNH, Financial) in one year is $708.96, suggesting a upside of 21.18% from the current price of $585.04. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the UnitedHealth Group Inc (UNH) Summary page.
